Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy

Ursu et al.(1) outline an absence of neurocognitive deficits and a reduction of anxiety measurements in a prospective single-center study of patients with lymphoma receiving CD19-directed chimeric antigen receptor (CAR) T-cell therapy. Despite the well-studied acute neurotoxicities of CAR T-cell therapy, delayed onset of cognitive dysfunction was not characterized in pivotal clinical trials. With roughly 60% CAR T-cell therapy patients experiencing acute neurologic symptoms to some degree, the postulated absence of long-term sequelae would be surprisingly encouraging.